Results 51 to 60 of about 762,287 (195)

Statin practices for ASCVD Prevention: A Cross-Sectional Analysis of Guideline Adherence in a High-Risk Local Patient Population

open access: yesJournal of the Pakistan Medical Association
Objectives: To investigate the current practices of statin prescription and use for primary and secondary prevention of atherosclerotic cardiovascular disease.
Rizwana Kitchlew   +4 more
doaj   +1 more source

Statin Therapy for Primary Prevention and Clinical Outcomes in Adults Aged 80 and Older: A Retrospective Comparative Cohort Study

open access: yesJournal of the American Geriatrics Society, Volume 74, Issue 6, Page 1687-1691, June 2026.
ABSTRACT Background Evidence supporting the use of statins for primary prevention of cardiovascular disease (CVD) in individuals aged ≥ 80 years remains limited. This study aimed to evaluate the long‐term clinical benefits and safety of statins for primary prevention in patients aged 80 years and older.
Ophir Lavon, Wafaa Hamodi, Sameer Kassem
wiley   +1 more source

Combination of Fimasartan and Statins in Patients With Hypertension and Dyslipidemia

open access: yesJournal of Lipid and Atherosclerosis
Objective We aimed to investigate the efficacy and safety of a combination of fimasartan 30 mg and moderate-intensity statins in patients with hypertension and dyslipidemia in a real-world setting.
Kyung Hoon Cho   +13 more
doaj   +1 more source

Aspirin with or without statin in the treatment of endotheliitis, thrombosis, and ischemia in coronavirus disease

open access: yesRevista da Sociedade Brasileira de Medicina Tropical, 2020
INTRODUCTION: In the genesis of coronavirus disease (COVID-19), there is a process of endotheliitis associated with thrombotic changes, no studies have reported the use of acetylsalicylic acid (ASA) as a possible therapeutic approach.
Francisco Kleyton Zacarias Florêncio   +3 more
doaj   +1 more source

Liver function testing in patients on HMG-CoA reductase inhibitors

open access: yes, 2011
PURPOSE: The Food and Drug Administration currently requires the labeling of HMG-CoA reductase inhibitors to recommend liver function tests (LFTs) before the start of therapy and at various intervals during therapy, depending on the specific agent.
Donahue, James G.   +4 more
core   +1 more source

High cholesterol absorption efficiency interferes with bile acid metabolism and cholesterol elimination from the body

open access: yesJournal of Internal Medicine, Volume 299, Issue 5, Page 628-638, May 2026.
Abstract Background Elevated low‐density lipoprotein (LDL) cholesterol causes atherosclerotic cardiovascular diseases. Variables of whole‐body cholesterol metabolism, for example, high cholesterol absorption efficiency, might also be atherogenic, whereas the role of bile acids is controversial.
Piia Simonen   +4 more
wiley   +1 more source

Uso de estatinas e o risco de Diabetes Mellitus tipo 2: Revisão Baseada na Evidência

open access: yesRevista Brasileira de Medicina de Família e Comunidade, 2016
Objetivo: Determinar se existe relação entre o uso de estatinas e a incidência de Diabetes Melittus tipo 2 (DM2). Métodos: Foram realizadas pesquisas nas bases de dados National Guidelines Clearinghouse, Cochrane Lybrary, Trip database, PubMed e MedLine ...
Susana Silva, Nuno Monteiro
doaj   +1 more source

Current Trends, Future Prospects and Constraints of Whole Microalgae and Their Fractions as a Functional Feed Ingredient for Animals

open access: yesJournal of Animal Physiology and Animal Nutrition, Volume 110, Issue 3, Page 324-338, May 2026.
ABSTRACT Microalgae are a highly diverse group of unicellular organisms that grow in a wide range of aquatic environments and are widely used as dietary supplements for both human and animal applications. Microalgae are rich in lipids, proteins, carbohydrates and other valuable bioactive components such as pigments, antioxidants and vitamins.
Sietse Jan Koopmans   +4 more
wiley   +1 more source

Inhibition of protein synthesis blocks the response to 25-hydroxycholesterol by inhibiting degradation of hydroxymethylglutaryl-CoA reductase.

open access: yes, 1982
The activity of the rate-limiting enzyme of the cholesterol biosynthetic pathway, 3-hydroxy-3-methylglutaryl coenzyme A reductase in Chinese hamster ovary (CHO) cells decreased more rapidly in cells treated with 25-hydroxycholesterol alone (t 1/2 = 1 ...
Kandutsch, A A, Chen, H W, Richards, B A
core   +1 more source

Home - About - Disclaimer - Privacy